浙江九洲药业股份有限公司关于开立募集资金现金管理产品专用结算账户及使用闲置募集资金进行现金管理的进展公告

Core Viewpoint - The company has approved the use of idle raised funds for cash management, amounting to 785 million RMB, to enhance fund efficiency while ensuring the safety and liquidity of investments [1][7][12]. Summary by Sections Cash Management Overview - The cash management is aimed at improving fund efficiency and ensuring the safety of raised funds while not affecting the ongoing investment projects [2][12]. - The cash management products include bank certificates of deposit with a management period of 3, 6, and 12 months [1][7]. Cash Management Amount and Source - The total amount for cash management is 785 million RMB [4][7]. - The funds are sourced from idle raised funds from the company's non-public offerings in 2020 and 2022 [4][6]. Previous Cash Management Activities - The company previously used 21 million RMB of idle funds for cash management, which was redeemed with the principal and earnings returned to the special account for raised funds [2][5]. Approval Process - The cash management proposal was approved in the board meeting held on December 13, 2024, allowing the company to use up to 1.2 billion RMB for cash management under specific conditions [1][9]. Cash Management Product Details - The cash management products are required to be of high safety and liquidity, and the company ensures that these do not alter the intended use of raised funds [7][12]. - The income generated from cash management will belong to the company and will be returned to the special account upon maturity [8][12]. Impact on Company Operations - The use of idle raised funds for cash management will not affect the company's daily operations or the normal implementation of investment projects, aiming to enhance returns for shareholders [12].